US 12,291,571 B2
Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody
Ana Kostic, New York, NY (US); Ludmila Kelly, Silver Spring, MD (US); Xia Liu, Hopewell Junction, NY (US); Brendan J. Classon, Seattle, WA (US); and Allen Radin, New York, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed on Jul. 13, 2022, as Appl. No. 17/864,000.
Application 17/864,000 is a continuation of application No. 16/910,884, filed on Jun. 24, 2020, granted, now 11,421,036.
Application 16/910,884 is a continuation of application No. 15/017,664, filed on Feb. 7, 2016, granted, now 10,730,948, issued on Aug. 4, 2020.
Application 15/017,664 is a continuation of application No. 14/328,336, filed on Jul. 10, 2014, granted, now 9,290,574, issued on Mar. 22, 2016.
Claims priority of provisional application 61/844,978, filed on Jul. 11, 2013.
Prior Publication US 2023/0272085 A1, Aug. 31, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 31/56 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01)
CPC C07K 16/2866 (2013.01) [A61K 9/0019 (2013.01); A61K 31/56 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/577 (2013.01); C07K 2317/21 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2318/00 (2013.01)] 27 Claims
 
1. A method of reducing eosinophilic infiltration, the method comprising:
administering to a subject one or more doses of an interleukin-4 receptor (IL-4R) inhibitor, wherein the subject to be treated exhibits ≥15 eosinophils per high power field in the mucosal lining of a region of the gastrointestinal tract;
wherein the IL-4R inhibitor is an antibody or antigen-binding fragment thereof that binds IL-4Rα and comprises a heavy chain complementarity determining region (HCDR)1 comprising the amino acid sequence of SEQ ID NO:3, an HCDR2 comprising the amino acid sequence of SEQ ID NO:4, an HCDR3 comprising the amino acid sequence of SEQ ID NO:5, a light chain complementarity determining region (LCDR)1 comprising the amino acid sequence of SEQ ID NO: 6, an LCDR2 comprising the amino acid sequence LGS, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:8.